Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Johnson & Johnson
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Posted inPharma & Biotech
Halozyme: Elegant Transformation of Drugs From Intravenous to Subcutaneous
Easy and quick administration of biological drugs. All for the convenience of patient care.
Posted inNeuroscience, New Drugs, Regulatory
Dayvigo: New Japanese Drug for Insomnia
Lemborexant by Eisai to help you fall asleep. Chronic sleep loss, go away!
Posted inOncology, Research
Not All Cancer Drugs Are Equally Useful
Cheating out of ignorance, or Sleight of hand and no fraud. How pharmaceutical companies scam clinical trials.